Gain Therapeutics, Inc. (GANX) vs Inovio Pharmaceuticals, Inc. (INO)
A side-by-side comparison of Gain Therapeutics, Inc. and Inovio Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GANX
Gain Therapeutics, Inc.
$1.74HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT
INO
Inovio Pharmaceuticals, Inc.
$1.15HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT
Total return — GANX vs INO
growth of $100 · dividends reinvested · last 6yGANX -84.9% (-27.0%/yr)INO -99.1% (-54.3%/yr)GANX compounded faster over this window
Log scale — wide-divergence pair
GANX INO
GANX vs INO: by the numbers
- •INO is the larger company ($79M vs $74M market cap).
- •Both run net losses; GANX's is the smaller (0.00% vs -130000.00% net margin).
Metrics side by side
Valuation
| Metric | GANX | INO |
|---|---|---|
| P/B ratio | 6.55 | 18.18 |
Profitability
| Metric | GANX | INO |
|---|---|---|
| Gross margin | 0.00% | 100.00% |
| Operating margin | 0.00% | -132871.32% |
| Net margin | 0.00% | -130000.00% |
| ROE | -178.06% | -1542.57% |
| ROIC | -159.24% | -836.58% |
Growth (annualized)
| Metric | GANX | INO |
|---|---|---|
| Total return CAGR (5Y) | -25.06% | -57.05% |
Frequently asked
- How have GANX and INO total returns compared?
- Over the past 5 years, GANX delivered -25.06% and INO delivered -57.05% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.